Jean-Christophe Lega
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jean-Christophe Lega has a total of 429 co-authors. Here are the top co-authors by number of shared publications:
Sabine Mainbourg
8 shared publications- Sabine Mainbourg
Service de Médecine Interne Et Pathologies Vasculaires, Centre Hospitalier Lyon Sud, Pierre-Bénite, France
7 shared publications - Hervé Lobbes
Service de Médecine Interne, Hôpital Estaing, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France
6 shared publications Isabelle Durieu
Department of Internal and Vascular Medicine, National Referral Centre for Rare Juvenile Rheumatological and Autoimmune Diseases (RAISE), Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France; Faculty of Medicine, Université de Lyon, Université Lyon 1, France; Lyon Immunopathology Federation (LIFE), University of Lyon, Hospices Civils de Lyon, France; Univ Lyon, Health Services and Performance Research EA7425, Claude Bernard University Lyon, F-69003, France
6 shared publicationsQuitterie Reynaud
Department of Internal and Vascular Medicine, National Referral Centre for Rare Juvenile Rheumatological and Autoimmune Diseases (RAISE), Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France; Faculty of Medicine, Université de Lyon, Université Lyon 1, France; Lyon Immunopathology Federation (LIFE), University of Lyon, Hospices Civils de Lyon, France; Univ Lyon, Health Services and Performance Research EA7425, Claude Bernard University Lyon, F-69003, France
6 shared publicationsLouis Terriou
21Service de Medecine Interne et d’Immunologie Clinique, Centre Hospitalier Universitaire de Lille, Lille, France
5 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 40 (6) , e70118
Hypothetico‐Deductive Reasoning in Direct Oral Anticoagulant Trial Meta‐Analyses: A Meta‐Epidemiological Study
Background: Direct oral anticoagulants (DOAC) have become standard therapy for thrombosis prevention since 2008. Meta‐analyses (MAs) of randomized controlled trials (RCT) are considered high‐level evidence supporting clinical guidelines. However, methodological biases may yield false‐positive findings, particularly through inadequate hypothesis formulation, multiple testing without alpha‐risk correction, and selective outcome reporting. No study has systematically assessed the risk of false positives in MA evaluating DOAC through hypothetico‐deductive reasoning. Objective: This study aimed to assess methodological features relevant to confirmatory inference in MA of RCTs evaluating DOACs, including hypothesis specification and multiplicity management, and to quantify nominal exposure to type I error under specified assumptions. Methods: Following a pre‐specified protocol, we conducted a meta‐epidemiological study using embase and PubMed databases. We included MA of RCT evaluating four EMA‐approved DOAC. Two independent authors performed study selection. For each MA, we calculated the nominal family‐wise probability of at least one type I error under the global null hypothesis, assuming independent tests. We assessed the presence of directional hypotheses, primary outcome definition, pre‐specified protocols, sensitivity analyses, and spin in conclusions. Results: Ninety‐three MA were included (mean 34 118 patients; seven RCT per MA). The median nominal family‐wise type I error probability was 40%, and only 2.2% of MAs reported alpha‐risk management, 26.9% had pre‐specified protocols, and 14.0% reported directional hypotheses. Only 5.4% combined a clearly specified directional hypothesis with a single primary objective and well‐defined outcome. Spin was present in 30.1% of conclusions. Conclusion: Most MAs showed substantial uncorrected nominal exposure to multiplicity; this estimate is a theoretical indicator and not the probability that a published conclusion is false. Many MAs also lacked explicit hypotheses and frequently exhibited spin. Strengthening reliability requires integrating genuine hypothetico‐deductive approaches and adapting methodological guidelines.
- 13 November 2026
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 40 (6) , e70118
Open AccessHypothetico‐Deductive Reasoning in Direct Oral Anticoagulant Trial Meta‐Analyses: A Meta‐Epidemiological Study
Background: Direct oral anticoagulants (DOAC) have become standard therapy for thrombosis prevention since 2008. Meta‐analyses (MAs) of randomized controlled trials (RCT) are considered high‐level evidence supporting clinical guidelines. However, methodological biases may yield false‐positive findings, particularly through inadequate hypothesis formulation, multiple testing without alpha‐risk correction, and selective outcome reporting. No study has systematically assessed the risk of false positives in MA evaluating DOAC through hypothetico‐deductive reasoning. Objective: This study aimed to assess methodological features relevant to confirmatory inference in MA of RCTs evaluating DOACs, including hypothesis specification and multiplicity management, and to quantify nominal exposure to type I error under specified assumptions. Methods: Following a pre‐specified protocol, we conducted a meta‐epidemiological study using embase and PubMed databases. We included MA of RCT evaluating four EMA‐approved DOAC. Two independent authors performed study selection. For each MA, we calculated the nominal family‐wise probability of at least one type I error under the global null hypothesis, assuming independent tests. We assessed the presence of directional hypotheses, primary outcome definition, pre‐specified protocols, sensitivity analyses, and spin in conclusions. Results: Ninety‐three MA were included (mean 34 118 patients; seven RCT per MA). The median nominal family‐wise type I error probability was 40%, and only 2.2% of MAs reported alpha‐risk management, 26.9% had pre‐specified protocols, and 14.0% reported directional hypotheses. Only 5.4% combined a clearly specified directional hypothesis with a single primary objective and well‐defined outcome. Spin was present in 30.1% of conclusions. Conclusion: Most MAs showed substantial uncorrected nominal exposure to multiplicity; this estimate is a theoretical indicator and not the probability that a published conclusion is false. Many MAs also lacked explicit hypotheses and frequently exhibited spin. Strengthening reliability requires integrating genuine hypothetico‐deductive approaches and adapting methodological guidelines.
- Open Access
- 1 October 2026
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 40 (6) , e70112
Vitamin D Supplementation and Mortality in the Elderly: A Review of a Meta‐Analysis of Randomized Controlled Trials Using the REB Method
Background: The results of randomized controlled trials (RCTs) regarding the effect of vitamin D supplementation on mortality reduction are conflicting. Objective: The aim of this study was to assess the level of evidence through a sensitivity analysis of the meta‐analysis by Shah et al. (2024) using the Rebuilt the Evidence Base (REB) method. Methods: The main inclusion criterion was a double‐blind, placebo‐controlled RCT design. The exclusion criteria were trials combining vitamin D with other nutrients and unpublished RCTs. The main outcome was all‐cause mortality. A bias analysis was performed, followed by a hypothetico‐deductive analysis to determine the confirmatory or exploratory nature of each RCT. The REB method was used to interpret the results and assess the level of evidence. Results: Among the 25 RCTs included in the meta‐analysis by Shah et al., the analysis was performed on 8 RCTs at low risk of bias including 30 320 participants. Seven RCTs raised some concerns, and two RCTs were at high risk of bias according to ROB2. Bias arose from the randomization process, deviations from intended interventions, missing outcome data, and selection of the reported results. The results were statistically significant, in favor of vitamin D supplementation: RR = 0.96 (95% CI [0.92, 1.00]), p = 0.04. No RCT was conclusive. Conclusion: According to the REB method, there is an evidence signal regarding the benefit of vitamin D supplementation in the population aged 75 and older, which remains to be confirmed.
- 1 October 2026
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 40 (6) , e70112
Open AccessVitamin D Supplementation and Mortality in the Elderly: A Review of a Meta‐Analysis of Randomized Controlled Trials Using the REB Method
Background: The results of randomized controlled trials (RCTs) regarding the effect of vitamin D supplementation on mortality reduction are conflicting. Objective: The aim of this study was to assess the level of evidence through a sensitivity analysis of the meta‐analysis by Shah et al. (2024) using the Rebuilt the Evidence Base (REB) method. Methods: The main inclusion criterion was a double‐blind, placebo‐controlled RCT design. The exclusion criteria were trials combining vitamin D with other nutrients and unpublished RCTs. The main outcome was all‐cause mortality. A bias analysis was performed, followed by a hypothetico‐deductive analysis to determine the confirmatory or exploratory nature of each RCT. The REB method was used to interpret the results and assess the level of evidence. Results: Among the 25 RCTs included in the meta‐analysis by Shah et al., the analysis was performed on 8 RCTs at low risk of bias including 30 320 participants. Seven RCTs raised some concerns, and two RCTs were at high risk of bias according to ROB2. Bias arose from the randomization process, deviations from intended interventions, missing outcome data, and selection of the reported results. The results were statistically significant, in favor of vitamin D supplementation: RR = 0.96 (95% CI [0.92, 1.00]), p = 0.04. No RCT was conclusive. Conclusion: According to the REB method, there is an evidence signal regarding the benefit of vitamin D supplementation in the population aged 75 and older, which remains to be confirmed.
- Open Access
- 19 September 2026
- Published by Wiley in Journal of Evaluation in Clinical Practice
- Vol. 32 (6) , e70608
From Inference to Ritual: Why Frequentist Statistics Became Hard to Understand and Teach in Medicine
Introduction: Frequentist statistical tools still structure a large part of biomedical research, regulatory evaluation, and medical teaching, even though their correct interpretation remains uncertain among students, clinicians, and readers of the literature. This misunderstanding is usually attributed to pedagogical shortcomings or individual cognitive errors. This article examines the structural reasons for this persistent misunderstanding. It argues that it arises from a combination of historical, methodological, semantic, and institutional factors rather than from a direct lack of technical training. Methods: The paper uses a selective narrative and historical analysis of the Bayes–Fisher–Neyman trajectory, of the language used to describe major frequentist tools, of the critiques of their ritualized use, and of their institutionalization in editorial, regulatory, and curricular settings. Its purpose is synthetic and argumentative, with a focus on medical education. Main Findings: The article argues that, in Fisher's framework, the p value was not an isolated signal but one element within a dense experimental architecture based on study design, sufficient statistics, and exhaustive extraction of information. The later shift toward a procedural and decision‐oriented meaning strengthened its widespread use as a simple decision tool but made its frequentist meaning less natural. This opacity is further reinforced by ambiguous terminology, by the separation between statistics and methodology in teaching, and by ritualization through editors, agencies, and curricula. Conclusion: Misunderstanding of frequentism in biomedicine should be seen as a structural problem of intelligibility. A realistic educational response requires reconnecting calculation, study design, history, epistemology, and language, so that teaching moves away from ritual use of tools and toward a more robust understanding of their meaning and limits.
- 19 September 2026
- Published by Wiley in Journal of Evaluation in Clinical Practice
- Vol. 32 (6) , e70608
Open AccessFrom Inference to Ritual: Why Frequentist Statistics Became Hard to Understand and Teach in Medicine
Introduction: Frequentist statistical tools still structure a large part of biomedical research, regulatory evaluation, and medical teaching, even though their correct interpretation remains uncertain among students, clinicians, and readers of the literature. This misunderstanding is usually attributed to pedagogical shortcomings or individual cognitive errors. This article examines the structural reasons for this persistent misunderstanding. It argues that it arises from a combination of historical, methodological, semantic, and institutional factors rather than from a direct lack of technical training. Methods: The paper uses a selective narrative and historical analysis of the Bayes–Fisher–Neyman trajectory, of the language used to describe major frequentist tools, of the critiques of their ritualized use, and of their institutionalization in editorial, regulatory, and curricular settings. Its purpose is synthetic and argumentative, with a focus on medical education. Main Findings: The article argues that, in Fisher's framework, the p value was not an isolated signal but one element within a dense experimental architecture based on study design, sufficient statistics, and exhaustive extraction of information. The later shift toward a procedural and decision‐oriented meaning strengthened its widespread use as a simple decision tool but made its frequentist meaning less natural. This opacity is further reinforced by ambiguous terminology, by the separation between statistics and methodology in teaching, and by ritualization through editors, agencies, and curricula. Conclusion: Misunderstanding of frequentism in biomedicine should be seen as a structural problem of intelligibility. A realistic educational response requires reconnecting calculation, study design, history, epistemology, and language, so that teaching moves away from ritual use of tools and toward a more robust understanding of their meaning and limits.
- Open Access
- 14 August 2026
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 199
Reliability of accelerated confirmatory trials during the COVID-19 pandemic: the consequences of low pretrial plausibility
- 14 August 2026
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 199
Open AccessReliability of accelerated confirmatory trials during the COVID-19 pandemic: the consequences of low pretrial plausibility
- Open Access
- 13 August 2026
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 40 (5) , e70110
Redefining Regulatory Proof: The End of the Two‐Trial Paradigm
The recent decision to establish a single pivotal trial as the default evidentiary standard for Food and Drug Administration (FDA) approval marks a substantive shift in the architecture of regulatory proof. This marks a shift from replication‐based validation to a coherence‐based model of sufficiency, beyond a procedural adjustment. Because FDA standards likely influence global development strategies, this change will likely extend beyond the United States. Although accelerating access and reducing development costs are legitimate objectives, the reform raises methodological and epistemological concerns. The statistical rationale does not fully incorporate the contextual factors that influence false‐positive risk, including prior plausibility and statistical power. Prior plausibility remains informal, and post‐marketing evidence seldom restores the epistemic security provided by independent replication. Replication is not merely a statistical redundancy but rather a structural safeguard of robustness and external validity. Without explicit safeguards, increased regulatory flexibility may generate heterogeneity in evidentiary thresholds and progressively weaken the discriminative function of health technology assessment.
- 13 August 2026
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 40 (5) , e70110
Open AccessRedefining Regulatory Proof: The End of the Two‐Trial Paradigm
The recent decision to establish a single pivotal trial as the default evidentiary standard for Food and Drug Administration (FDA) approval marks a substantive shift in the architecture of regulatory proof. This marks a shift from replication‐based validation to a coherence‐based model of sufficiency, beyond a procedural adjustment. Because FDA standards likely influence global development strategies, this change will likely extend beyond the United States. Although accelerating access and reducing development costs are legitimate objectives, the reform raises methodological and epistemological concerns. The statistical rationale does not fully incorporate the contextual factors that influence false‐positive risk, including prior plausibility and statistical power. Prior plausibility remains informal, and post‐marketing evidence seldom restores the epistemic security provided by independent replication. Replication is not merely a statistical redundancy but rather a structural safeguard of robustness and external validity. Without explicit safeguards, increased regulatory flexibility may generate heterogeneity in evidentiary thresholds and progressively weaken the discriminative function of health technology assessment.
- Open Access
- 11 August 2026
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 199
The erosion of proof in paradigm transitions: the rise of narrative rationality in health technology assessment
- 11 August 2026
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 199
Open AccessThe erosion of proof in paradigm transitions: the rise of narrative rationality in health technology assessment
- 27 November 2025
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (2) , 1171-1179
Characteristics of patients with major relapse in giant cell arteritis: a multicenter case–control study
Objectives The objective was to identify predictive factors for major relapses (MR) in patients with giant cell arteritis (GCA) and to compare clinical characteristics between MR phenotypes. Method This multicenter retrospective case–control study included patients fulfilling GiaCTA criteria for GCA. Cases were patients experiencing MR according to 2018 EULAR definitions. Controls were GCA patients without MR with a 1:3 ratio. Data were collected and analyzed using univariate and multivariate logistic regression to determine factors independently associated with MR. MR was subclassified into cranial-MR and large-vessel-MR which were compared using appropriate statistical tests. Results 258 patients were included, 70 cases and 188 controls (48.4% minor relapse, and 24.4% without relapse). The mean age at diagnosis was 72.5 ± 8.6 years, 70,9% were females. Younger age at diagnosis was associated with an increased risk of MR (OR = 0.93 per 10 years, 95% CI [0.87; 0.999], p = 0.043). No other clinically significant risk factors were identified. Among the 70 cases, 48.6% had a cranial-MR and 51.4% a large-vessel-MR. Patients with a cranial-MR were older (74.3 ± 6.3 years vs. 67.3 ± 7.0 years, p < 0.001) and were more likely to have cranial symptoms at diagnosis of GCA (91.2% vs. 69.4%, p = 0.023) compared to those with a large-vessel-MR. Compared with cranial-MR, large-vessel MR was more frequent in women (80.5% vs. 52.9%, p < 0.01) and tended to be associated with aortitis at diagnosis (70.0% vs. 43.5%, p = 0.052). Conclusions Younger age at diagnosis was the only independent predictor of MR. Relapse patterns mirrored initial disease phenotype, supporting the existence of cranial and large-vessel GCA subtypes. Key Points •Younger age at diagnosis is associated with a higher risk of major relapse in giant cell arteritis. •Cranial and large-vessel major relapses display distinct clinical patterns, often mirroring the initial disease phenotype. •No strong laboratory or imaging predictor of major relapse was identified in this multicentre case–control study.
- 27 November 2025
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (2) , 1171-1179
Characteristics of patients with major relapse in giant cell arteritis: a multicenter case–control study
Objectives The objective was to identify predictive factors for major relapses (MR) in patients with giant cell arteritis (GCA) and to compare clinical characteristics between MR phenotypes. Method This multicenter retrospective case–control study included patients fulfilling GiaCTA criteria for GCA. Cases were patients experiencing MR according to 2018 EULAR definitions. Controls were GCA patients without MR with a 1:3 ratio. Data were collected and analyzed using univariate and multivariate logistic regression to determine factors independently associated with MR. MR was subclassified into cranial-MR and large-vessel-MR which were compared using appropriate statistical tests. Results 258 patients were included, 70 cases and 188 controls (48.4% minor relapse, and 24.4% without relapse). The mean age at diagnosis was 72.5 ± 8.6 years, 70,9% were females. Younger age at diagnosis was associated with an increased risk of MR (OR = 0.93 per 10 years, 95% CI [0.87; 0.999], p = 0.043). No other clinically significant risk factors were identified. Among the 70 cases, 48.6% had a cranial-MR and 51.4% a large-vessel-MR. Patients with a cranial-MR were older (74.3 ± 6.3 years vs. 67.3 ± 7.0 years, p < 0.001) and were more likely to have cranial symptoms at diagnosis of GCA (91.2% vs. 69.4%, p = 0.023) compared to those with a large-vessel-MR. Compared with cranial-MR, large-vessel MR was more frequent in women (80.5% vs. 52.9%, p < 0.01) and tended to be associated with aortitis at diagnosis (70.0% vs. 43.5%, p = 0.052). Conclusions Younger age at diagnosis was the only independent predictor of MR. Relapse patterns mirrored initial disease phenotype, supporting the existence of cranial and large-vessel GCA subtypes. Key Points •Younger age at diagnosis is associated with a higher risk of major relapse in giant cell arteritis. •Cranial and large-vessel major relapses display distinct clinical patterns, often mirroring the initial disease phenotype. •No strong laboratory or imaging predictor of major relapse was identified in this multicentre case–control study.
- Open Access
Efficacy and safety of balneotherapy in rheumatology: a systematic review and meta-analysis
Objective The efficacy of balneotherapy in rheumatology remains unclear. We aimed to estimate its benefits and risks in rheumatology. Methods We conducted a systematic review of randomised trials assessing any European balneotherapy for a rheumatological indication in adults versus any control, on clinical outcomes. We searched PubMed, Cochrane Library, Embase and https://clinicaltrials.gov/ (up to 28 November 2023). We used the Cochrane risk of bias tool version 2, funnel plot and asymmetry tests. We used a random effects model with an inverse-variance weighting method for standardised mean difference (SMD) and risk ratio (RR). We used the Grading of Recommendations Assessment, Development and Evaluation approach for two primary outcomes, pain and quality of life (QoL) at 3 months, and two safety outcomes, withdrawal and any adverse event (AE). Results We included 29 trials in mechanical disorders, 9 in inflammatory diseases and 4 in fibromyalgia. The synthesis suggested a decrease in pain of a very low level of certainty (SMD: −0.72 (95% CI (−1.00; −0.44)), very serious risk of bias and of inconsistency, publication bias strongly suspected); an increase in QoL of a very low level of certainty (SMD: 0.56 (95% CI (0.37; 0.75)), very serious risk of bias and serious risk of inconsistency); inconclusive results regarding the risk of withdrawal (RR: 0.75 (95% CI (0.46; 1.20)), very serious risk of bias and serious risk of imprecision) and of AE (RR: 0.80 (95% CI (0.43; 1.50)), serious risk of bias and of inconsistency and very serious risk of imprecision). Conclusion The certainty of the effect of balneotherapy in rheumatology was very low. PROSPERO registration number CRD42023448206.
Open AccessEfficacy and safety of balneotherapy in rheumatology: a systematic review and meta-analysis
Objective The efficacy of balneotherapy in rheumatology remains unclear. We aimed to estimate its benefits and risks in rheumatology. Methods We conducted a systematic review of randomised trials assessing any European balneotherapy for a rheumatological indication in adults versus any control, on clinical outcomes. We searched PubMed, Cochrane Library, Embase and https://clinicaltrials.gov/ (up to 28 November 2023). We used the Cochrane risk of bias tool version 2, funnel plot and asymmetry tests. We used a random effects model with an inverse-variance weighting method for standardised mean difference (SMD) and risk ratio (RR). We used the Grading of Recommendations Assessment, Development and Evaluation approach for two primary outcomes, pain and quality of life (QoL) at 3 months, and two safety outcomes, withdrawal and any adverse event (AE). Results We included 29 trials in mechanical disorders, 9 in inflammatory diseases and 4 in fibromyalgia. The synthesis suggested a decrease in pain of a very low level of certainty (SMD: −0.72 (95% CI (−1.00; −0.44)), very serious risk of bias and of inconsistency, publication bias strongly suspected); an increase in QoL of a very low level of certainty (SMD: 0.56 (95% CI (0.37; 0.75)), very serious risk of bias and serious risk of inconsistency); inconclusive results regarding the risk of withdrawal (RR: 0.75 (95% CI (0.46; 1.20)), very serious risk of bias and serious risk of imprecision) and of AE (RR: 0.80 (95% CI (0.43; 1.50)), serious risk of bias and of inconsistency and very serious risk of imprecision). Conclusion The certainty of the effect of balneotherapy in rheumatology was very low. PROSPERO registration number CRD42023448206.
- 9 January 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (2) , 244-247
Long-term follow-up of the STOPAGO study
In an open prospective, multicenter study enrolling 48 selected patients with chronic immune thrombocytopenia who achieved complete response for 1 year on thrombopoietin receptor agonists, half of the patients maintained a sustained response off treatment 4 years after treatment discontinuation.
- 9 January 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (2) , 244-247
Long-term follow-up of the STOPAGO study
In an open prospective, multicenter study enrolling 48 selected patients with chronic immune thrombocytopenia who achieved complete response for 1 year on thrombopoietin receptor agonists, half of the patients maintained a sustained response off treatment 4 years after treatment discontinuation.
- Open Access
Vasodilator drugs and heart-related outcomes in systemic sclerosis: an exploratory analysis
Background and aims Systemic sclerosis (SSc) is an autoimmune connective disease characterised by excessive extracellular matrix deposition and widespread skin and internal organ fibrosis including various cardiac manifestations. Heart involvement is one of the leading causes of death among patients with SSc. In this study, we aimed to assess the effect of various vasodilator treatments. Methods We used data from a national multicentric prospective study using the French SSc national database. We estimated the average treatment effect (ATE) of sildenafil, bosentan, angiotensin-converting enzyme (ACE) inhibitors and iloprost on diastolic dysfunction, altered ejection fraction Results We included 1048 patients with available data regarding treatment. Regarding sildenafil analyses, the ATE on diastolic dysfunction at 3 years was −2.83% (95% CI −4.06; −1.60, pConclusions Using causal methods, our study is the first and largest suggesting that sildenafil might have benefits among SSc patients regarding diastolic dysfunction and altered ejection fraction occurrence. However, further studies assessing the effect of vasodilators on heart-related outcome among SSc patients are needed to confirm those exploratory results.
Open AccessVasodilator drugs and heart-related outcomes in systemic sclerosis: an exploratory analysis
Background and aims Systemic sclerosis (SSc) is an autoimmune connective disease characterised by excessive extracellular matrix deposition and widespread skin and internal organ fibrosis including various cardiac manifestations. Heart involvement is one of the leading causes of death among patients with SSc. In this study, we aimed to assess the effect of various vasodilator treatments. Methods We used data from a national multicentric prospective study using the French SSc national database. We estimated the average treatment effect (ATE) of sildenafil, bosentan, angiotensin-converting enzyme (ACE) inhibitors and iloprost on diastolic dysfunction, altered ejection fraction Results We included 1048 patients with available data regarding treatment. Regarding sildenafil analyses, the ATE on diastolic dysfunction at 3 years was −2.83% (95% CI −4.06; −1.60, pConclusions Using causal methods, our study is the first and largest suggesting that sildenafil might have benefits among SSc patients regarding diastolic dysfunction and altered ejection fraction occurrence. However, further studies assessing the effect of vasodilators on heart-related outcome among SSc patients are needed to confirm those exploratory results.